Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy
Public ClinicalTrials.gov record NCT01728077. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy Phase 3b
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
N01372 study is to evaluate the long-term safety, tolerability, maintenance of efficacy of Brivaracetam (BRV); as well as the effect of BRV on subjects' health-related quality of life and to explore the direct medical resource use for BRV (for subjects entering N01372 from a study where pharmacoeconomic data was collected). BRV will be used at doses up to maximum of 200 mg/day, as adjunctive treatment in subjects aged 16 years or older with Epilepsy.
Study identification
- NCT ID
- NCT01728077
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 26 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2012
- Primary completion
- Jul 31, 2016
- Completion
- Jul 31, 2016
- Last update posted
- Jul 10, 2018
2012 – 2016
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 103 | Little Rock | Arkansas | — | — |
| 108 | Lexington | Kentucky | — | — |
| 109 | New York | New York | — | — |
| 106 | Akron | Ohio | — | — |
| 110 | Dallas | Texas | — | — |
| 102 | Salt Lake City | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
Recently updated Epilepsy trials
Other public records listing Epilepsy. Sorted by last update posted; newest first. Not a recommendation.
- NCT07768618: Electrophysiologic Mechanisms of Ketamine Antidepressant Response Not yet recruiting
- NCT07750496: Outcomes After Planned Discontinuation of AntiSeizure Medication Recruiting
- NCT07735715: HOBSCOTCH-YOUTH and Young Adults Not yet recruiting
- NCT06135285: A Device to Prevent Sudden Unexpected Death in Epilepsy: Detecting Peri-Ictal Body Position Not yet recruiting
- NCT05954182: Cognitive Enhancement Intervention for Creating a Healthy L.I.F.E (Lifestyle Interventions for Epilepsy) Active, not recruiting
- NCT04715646: A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01728077, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 10, 2018 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01728077 live on ClinicalTrials.gov.